Artelo Biosciences, Inc. cash flow to debt ratio of -1.26K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Artelo Biosciences, Inc.'s free cash flow has decreased 2.04% from $-8.35M last year to $-8.52M, signaling decreasing performance

Artelo Biosciences, Inc.'s debt to equity ratio is 0.11, which means that the company's assets are healthy financed, signaling financial stability.

Artelo Biosciences, Inc.'s debt has increased relative to shareholder equity from 0.04 last year to 0.11 today, signaling weakened financials

Artelo Biosciences, Inc. has negative EBITDA, making leverage ratio unreliable

Artelo Biosciences, Inc.'s interest coverage ratio is -17.13, which means that the company struggles to meet interest obligations, signaling financial risk.

Artelo Biosciences, Inc. has insufficient data to evaluate this check.

Artelo Biosciences, Inc.'s short-term liabilities of $4.04M exceed its short-term assets of $695.00K, signaling financial risk

Artelo Biosciences, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Artelo Biosciences, Inc.'s return on equity of -1.60K%, is lower than 15.00%, indicating bad performance

Artelo Biosciences, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Artelo Biosciences, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Artelo Biosciences, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Artelo Biosciences, Inc. has negative free cash flow, indicating cash burn

Artelo Biosciences, Inc.'s yearly earnings has decreased 31.07% since last year from $-9.83M to $-12.88M, signaling decreasing performance

Artelo Biosciences, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -158.49% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Artelo Biosciences, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Artelo Biosciences, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Artelo Biosciences, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Artelo Biosciences, Inc. has insufficient data to evaluate this check.

Artelo Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Artelo Biosciences, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Artelo Biosciences, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Artelo Biosciences, Inc. has insufficient data to evaluate this check.

Artelo Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Artelo Biosciences, Inc. has a price-to-book ratio of 0.08x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Artelo Biosciences, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue